213902-34-2

Upstream product

• 218152-30-8 N²-acetyl-O⁶-(2-(p-nitrophenyl)ethyl)guanine 
• 917376-69-3 N²,N⁹-diacetyl-O⁶-2-(4-nitrophenyl)ethylguanine 
• 100-27-6 2-(4-nitrophenyl)ethanol 
• 10310-21-1 2-Amino-6-chloropurin 
• 3056-33-5 2,9-diacetylguanine 

Downstream Products

• 213487-34-4 {(2R,3R,4S,5R)-2-[6-[2-(4-Nitro-phenyl)-ethoxy]-2-(trimethylsilanyl-amino)-purin-9-yl]-4-trimethylsilanyloxy-5-trimethylsilanyloxymethyl-tetrahydro-furan-3-yl}-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 213487-39-9 {9-{(2R,3R,4S,5R)-5-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-4-hydroxy-3-[2-(4-nitro-phenyl)-ethoxycarbonylamino]-tetrahydro-furan-2-yl}-6-[2-(4-nitro-phenyl)-ethoxy]-9H-purin-2-yl}-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 213487-37-7 (6-[2-(4-Nitro-phenyl)-ethoxy]-9-{(2R,3R,3aS,9aR)-5,5,7,7-tetraisopropyl-3-[2-(4-nitro-phenyl)-ethoxycarbonylamino]-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-9H-purin-2-yl)-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 213487-38-8 {9-{(2R,3R,4S,5R)-4-Hydroxy-5-hydroxymethyl-3-[2-(4-nitro-phenyl)-ethoxycarbonylamino]-tetrahydro-furan-2-yl}-6-[2-(4-nitro-phenyl)-ethoxy]-9H-purin-2-yl}-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 213487-36-6 ((2R,3R,3aS,9aR)-2-{2-Amino-6-[2-(4-nitro-phenyl)-ethoxy]-purin-9-yl}-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-3-yl)-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 213487-35-5 ((2R,3R,4S,5R)-2-{2-Amino-6-[2-(4-nitro-phenyl)-ethoxy]-purin-9-yl}-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-3-yl)-carbamic acid 2-(4-nitro-phenyl)-ethyl ester 
• 917376-87-5 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-{5-O-(4,4'-dimethoxytrityl)-2-O-[2-(4-nitrophenyl)ethoxycarbonyl]-α-D-arabinofuranosyl}guanine 
• 917376-86-4 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-{5-O-(4-monomethoxytrityl)-2-O-[2-(4-nitrophenyl)ethoxycarbonyl]-α-D-arabinofuranosyl}guanine 
• 917474-26-1 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-{3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-O-[2-(4-nitrophenyl)ethoxycarbonyl]-α-D-arabinofuranosyl}guanine 
• 917376-75-1 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)guanine 
• 917376-79-5 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-α-D-arabinofuranosyl]guanine 
• 917376-84-2 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-{2-O-[2-(4-nitrophenyl)ethoxycarbonyl]-α-D-arabinofuranosyl}guanine 
• 917376-74-0 O⁶-[2-(4-nitrophenyl)ethyl]-9-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl)guanine 
• 917376-76-2 O⁶-[2-(4-nitrophenyl)ethyl]-N²-[2-(4-nitrophenyl)ethoxycarbonyl]-9-(α-D-arabinofuranosyl)guanine 

Relevant academic research and scientific papers

Effect of O6-substituted guanine analogs on O6-methylguanine DNA-methyltransferase Expression and glioblastoma cells viability

Background: Glioblastoma multiforme (GBM) is often associated with a poor survival prognostic for patients. The main reason seems to be the acquired or inherent resistance to the chemotherapeutic agent used to treat the tumor, temozolomide (TMZ). To this day, the most recognized pathway of resistance is the DNA Direct Repair pathway by the means of the protein O6-methylguanine DNA-methyltransferase (MGMT). Objectives: To design and synthesize a series of MGMT inhibitors that can sensitize GBM cells to TMZ. Methods: Twenty-five O6-alkyl, O6-aryl and O6-substituted-aryl guanine analogs including nine novel compounds were synthesized, characterized, analyzed by molecular docking and tested on the T98G GBM cells viability. Results: Following molecular modeling with MGMT, the newly designed compounds 19, 22, and 24 emerged as the most promising MGMT ligands and displayed modest cytotoxicity. Guanine analog (19), bearing a p-nitrobenzyl moiety, reduced considerably the O6-methylguanine DNA-methyltransferase expression level. When combined with TMZ (1), which is used as first line treatment for brain tumors, compounds 19, 22, and 24 decreased T98G cells?proliferation by 32%, 68% and 50%, respectively. TMZ (1) displayed negligible effect on the proliferation of these cells further supporting the notion that this cell model is resistant to this alkylating agent. Conclusion: Overall, these results notably highlight a group of MGMT inhibitors that warrants further exploration in the development of therapeutic options to circumvent TMZ resistance in brain tumors.

Nucleotides. LXXIV* synthesis of α-D-arabino-oligonucleotides

□ The 5 α-D-arabinofuranosylnucleosides α-araU (15), α-araT (18), α-araC (22), α-araA (25), and α-araG (28) have been synthesized by the modified silyl-method. The amino groups at the nucleobases and the 2′-hydroxy group at the sugar moiety were protected by the 2-(4-nitrophenyl)ethoxycarbonyl (npeoc) group (37-40) and the amide function in α-araG was additionally blocked by the 2-(4-nitrophenyl)ethyl group (63) to improve solubility in organic solvents. Mono-and dimethoxytritylation of the 5′-OH group was performed in the usual manner to give 41-48, 64, and 65 in high yields and further substitution of the 3′-OH group led to the monomeric building blocks 66-75 as well as the 3′-O-succinoyl derivatives 76-85 functioning as starting units in solid-support oligonucleotide synthesis. A large number of oligo-α- arabinonucleotides have been prepared on modified CPG-material applying the npeoc/npe strategy as a very efficient synthetic tool for highly purified, homogenous oligomers. Hybridizations between α-arabinonucleotide strands revealed in analogy to earlier findings an antiparallel orientation whereas the combination of an oligo-α-D-arabinonucleotide with a complementary oligo-2′-deoxy-β-D-ribofuranosylnucleotide showed base-pairing only if a parallel polarity was present. The advantages in oligo-α-arabino- nucleotide synthesis were furthermore demonstrated by the synthesis of the tα-ANAhis a structural analog of the natural tRNAhis of the phage T5. Copyright Taylor & Francis Group, LLC.